ATE244220T1 - Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung - Google Patents

Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung

Info

Publication number
ATE244220T1
ATE244220T1 AT95932172T AT95932172T ATE244220T1 AT E244220 T1 ATE244220 T1 AT E244220T1 AT 95932172 T AT95932172 T AT 95932172T AT 95932172 T AT95932172 T AT 95932172T AT E244220 T1 ATE244220 T1 AT E244220T1
Authority
AT
Austria
Prior art keywords
inhibitors
pharmaceutically acceptable
production
acat
heterocyclic compounds
Prior art date
Application number
AT95932172T
Other languages
English (en)
Inventor
Hiroshi Matsui
Shoji Kamiya
Hiroaki Shirahase
Shohei Nakamura
Katsuo Wada
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE244220T1 publication Critical patent/ATE244220T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
AT95932172T 1994-09-20 1995-09-20 Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung ATE244220T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22516694A JP3720395B2 (ja) 1994-09-20 1994-09-20 新規ヘテロ環誘導体、その製造方法およびその医薬用途
PCT/JP1995/001873 WO1996009287A1 (en) 1994-09-20 1995-09-20 Novel heterocyclic derivatives, process for producing the same, and medicinal use thereof

Publications (1)

Publication Number Publication Date
ATE244220T1 true ATE244220T1 (de) 2003-07-15

Family

ID=16824983

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01114083T ATE255091T1 (de) 1994-09-20 1995-09-20 1-acetyl-5-bromo-4,6-dimethylindolin
AT95932172T ATE244220T1 (de) 1994-09-20 1995-09-20 Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01114083T ATE255091T1 (de) 1994-09-20 1995-09-20 1-acetyl-5-bromo-4,6-dimethylindolin

Country Status (13)

Country Link
US (4) US5990150A (de)
EP (2) EP1136474B1 (de)
JP (1) JP3720395B2 (de)
KR (1) KR100365503B1 (de)
AT (2) ATE255091T1 (de)
AU (1) AU693261B2 (de)
CA (1) CA2200472A1 (de)
DE (2) DE69531213T2 (de)
DK (2) DK1136474T3 (de)
ES (2) ES2200003T3 (de)
HK (1) HK1040513B (de)
PT (2) PT782986E (de)
WO (1) WO1996009287A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720395B2 (ja) 1994-09-20 2005-11-24 京都薬品工業株式会社 新規ヘテロ環誘導体、その製造方法およびその医薬用途
KR100388345B1 (ko) * 1995-10-05 2004-03-30 교토 야쿠힝 고교 가부시키가이샤 신규헤테로시클릭유도체및이것의의약용도
US5861496A (en) * 1996-11-07 1999-01-19 Incyte Pharmaceuticals, Inc. Human squalene epoxidase
US20060046841A1 (en) * 2004-11-12 2006-03-02 Walker Jay S Budget-based flat rate play contract parameters
AR008331A1 (es) * 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
US5929250A (en) * 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
AR015425A1 (es) * 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
IL137229A0 (en) 1998-01-14 2001-07-24 Uab Research Foundation Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
EP1098884A4 (de) * 1998-07-23 2003-01-22 Smithkline Beecham Corp Il-8-rezeptor-antagonisten
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
AU8254101A (en) * 2000-09-01 2002-03-22 Sankyo Co Medicinal compositions
TW200600497A (en) 2001-02-02 2006-01-01 Sankyo Co Preparation of indoline derivative
WO2002072147A1 (fr) * 2001-03-14 2002-09-19 Sankyo Company, Limited Compositions medicinales contenant un inhibiteur de transporteur d'acide biliaire
EP1421953A4 (de) * 2001-08-28 2004-09-15 Sankyo Co Medizinische zusammensetzungen mit dem angiotensin-ii-rezeptorantagonist
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
AU2003252638B8 (en) * 2002-07-17 2009-03-05 Kyoto Pharmaceutical Industries, Ltd. Novel indoline compound and medicinal use thereof
US7205329B2 (en) * 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
US20070161698A1 (en) * 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
JP2007527397A (ja) * 2003-07-01 2007-09-27 マイクロバイア インコーポレイテッド Ｃｏｘ−２及びｆａａｈ阻害剤
US20070293542A1 (en) * 2003-10-16 2007-12-20 Cali Brian M Selective Cox-2 Inhibitors
EP2428516A1 (de) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Neue Phosphor enthaltende Thyromimetika
US20050234244A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Synthesis of COX-2 and FAAH inhibitors
US20050234030A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
ES2439229T3 (es) 2004-10-06 2014-01-22 The Brigham And Women's Hospital, Inc. Relevancia de niveles logrados de marcadores de inflamación sistémica tras el tratamiento
US7923573B2 (en) * 2004-10-27 2011-04-12 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
US8022188B2 (en) * 2006-04-24 2011-09-20 Abbott Laboratories Immunosuppressant binding antibodies and methods of obtaining and using same
US7883855B2 (en) * 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
ES2405364T3 (es) * 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
ES2393135T3 (es) 2006-12-29 2012-12-18 Abbott Laboratories Ensayo mejorado para fármacos inmunosupresores
US7914999B2 (en) * 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
WO2008082984A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
WO2009078875A1 (en) * 2007-12-19 2009-06-25 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1169450B (de) * 1960-08-19 1964-05-06 Hoechst Ag Verfahren zur Herstellung von Indolinderivaten und deren Salzen
US3824230A (en) * 1969-11-03 1974-07-16 Upjohn Co 1,2,4,5-tetrahydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 1,2,4,5-tetrahydropyrrolo(1,2,3-ef)(2,5)benzodiazepin-6(7h)-ones
JPS5484572A (en) * 1977-12-14 1979-07-05 Mitsui Petrochem Ind Ltd Preparation of 1-acyl-5-bromoindoline
US4615966A (en) * 1985-07-03 1986-10-07 Polaroid Corporation Color transfer photographic processes and products with indole phthalein filter dyes
JPH02117651A (ja) * 1988-01-20 1990-05-02 Yamanouchi Pharmaceut Co Ltd ジウレア誘導体及びその製造法
JPH0753714B2 (ja) * 1988-07-12 1995-06-07 武田薬品工業株式会社 Ａｃａｔ阻害剤、キノリン誘導体及びその製造法
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
EP0375133A1 (de) * 1988-11-14 1990-06-27 The Upjohn Company Alpha-amino-indol-3-essigsäure, verwendbar als antidiabetische, antifettleibige und antiarteriosklerotische Agenten
EP0427860A1 (de) * 1989-03-31 1991-05-22 Kyoto Pharmaceutical Industries, Ltd. Imidazol-derivate, verfahren zur herstellung und verwendung als arzneimittel
JPH03181465A (ja) * 1989-12-11 1991-08-07 Takeda Chem Ind Ltd キノリン誘導体
JPH0466568A (ja) * 1990-06-29 1992-03-02 Takeda Chem Ind Ltd 中枢性抗酸化剤化合物
US5143919A (en) * 1990-08-17 1992-09-01 Takeda Chemical Industries, Ltd. Thienopyridine derivatives and their pharmaceutical use
US5256782A (en) * 1990-08-17 1993-10-26 Takeda Chemical Industries, Ltd. Thienopyridine derivatives which are intermediates
FR2673625B1 (fr) * 1991-03-08 1993-05-07 Adir Nouveaux derives d'acylaminophenol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5254919A (en) 1991-03-22 1993-10-19 Eastman Kodak Company Encoder system using linear array sensor for high resolution
FR2674522B1 (fr) 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
JPH0825973B2 (ja) * 1991-04-12 1996-03-13 シェリング・コーポレーション アシル補酵素ａ：コレステロールアシルトランスフェラーゼの阻害剤としての二環式アミド
IL101785A0 (en) * 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
WO1994014801A1 (en) * 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
JP3720395B2 (ja) 1994-09-20 2005-11-24 京都薬品工業株式会社 新規ヘテロ環誘導体、その製造方法およびその医薬用途
KR100388345B1 (ko) * 1995-10-05 2004-03-30 교토 야쿠힝 고교 가부시키가이샤 신규헤테로시클릭유도체및이것의의약용도

Also Published As

Publication number Publication date
KR970706252A (ko) 1997-11-03
EP0782986A1 (de) 1997-07-09
JP3720395B2 (ja) 2005-11-24
ATE255091T1 (de) 2003-12-15
WO1996009287A1 (en) 1996-03-28
DK0782986T3 (da) 2003-10-06
DE69531213D1 (de) 2003-08-07
DE69531213T2 (de) 2004-04-15
US6489475B2 (en) 2002-12-03
AU693261B2 (en) 1998-06-25
DE69532216T2 (de) 2004-09-16
PT782986E (pt) 2003-11-28
AU3532495A (en) 1996-04-09
DE69532216D1 (de) 2004-01-08
US20010014740A1 (en) 2001-08-16
US5990150A (en) 1999-11-23
ES2200003T3 (es) 2004-03-01
DK1136474T3 (da) 2004-02-23
ES2206367T3 (es) 2004-05-16
HK1040513B (en) 2004-06-18
CA2200472A1 (en) 1996-03-28
JPH0892210A (ja) 1996-04-09
EP0782986A4 (de) 2000-04-05
HK1040513A1 (en) 2002-06-14
PT1136474E (pt) 2004-04-30
EP0782986B1 (de) 2003-07-02
KR100365503B1 (ko) 2003-06-12
EP1136474A1 (de) 2001-09-26
US6127403A (en) 2000-10-03
EP1136474B1 (de) 2003-11-26
US6414012B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
DE69531213D1 (de) Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung
DE59402222D1 (de) Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP0866059A4 (de) Neue heterozyklische derivate und ihre medizinische anwendung
DE69723869D1 (de) Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
PL304063A1 (en) Derivatives of 5-amino 9-methyl-7-pyrolidine-quinoline-3-carboxylic acid, method of obtaining them, pharmaceutic agent containing such compounds and medical treatment method employing them
ATE143020T1 (de) Aminocarbonylcarbamate verwandt mit physostigmin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE206926T1 (de) Verwendung eines phosphorsäurediesters zur herstellung eines arzneimittels zur behandlung von akne
ATE420853T1 (de) 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung
ATE124408T1 (de) Heterozyklische aminderivate, deren herstellung und deren verwendung.
ATE159029T1 (de) Phosphonsäurederivate, verfahren zur herstellung und ihre verwendung
ATE165822T1 (de) Chinolin-4-carbonylguanidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
US5434177A (en) Imidazoles for the treatment of age-related cognitive disorders and alzheimer
NO891071L (no) Fremgangsmaate for fremstilling av 4,5,6,7-tetrahydro-isotiazolo(4,5-c)-pyridinderivater og isomere.
DE68914600D1 (de) Kondensierte heterocyclische Derivate von 1,2,3,4-Tetrahydroacridin, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament.
ATE123493T1 (de) 3-(1h-indazol-3-yl)-4-pyridiname, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als arzneimittel.
DE69713648D1 (de) Benzopyranderivate und ihre Verwendung zur Behandlung von Herzkrankheiten
ATE144507T1 (de) Dithian substituierte retinoide, ihre verwendung, verfahren zu ihrer herstellung, diese enthaltende kosmetische und pharmazeutische zusammensetzungen und ihre therapeutische verwendung
ATE124692T1 (de) 1,4-benzodioxanderivate, verfahren zu deren herstellung, pharmakologische zusammensetzung und deren verwendung.
DE3671017D1 (de) Benzo(c)-1,5-naphthyridine, ein verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als arzneimittel.
HUP9900916A2 (hu) Benzotiofénszármazékok felhasználása az érszövetek kalciumvezetékeit antagonizáló hatású gyógyszerkészítmények előállítására
AU2013888A (en) Uricosuric composition
ATE181331T1 (de) Salmycine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
HU217346B (hu) Eljárás amlodipin-bezilát előállítására
RU94022252A (ru) Производные акриловой кислоты, амины, используемые для получения данных производных, способ предотвращения или лечения заболевания

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0782986

Country of ref document: EP

REN Ceased due to non-payment of the annual fee